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What are local issues? The problem of the local review of
research
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Local issues should be addressed through the governance framework and not through the research
ethics committee system
Abstract
Local review of research by ethics committees in the UK has long been held to be an
important right of the local research ethics committee and, even with the introduction
of the European Clinical Trials Directive, the governance arrangements for research
ethics committees continue to allow for local review of multicentre studies. There is no
requirement for local review in either the European Union directive or in the
guidelines on good clinical practice, and there is little evidence of it anywhere else in
Europe. The idea that there can be ‘‘local’’, as opposed to ‘‘central’’ ethical issues in
research is an interesting one, which raises important issues about the nature of
research ethics and ethical review. The aim of this paper is to argue that there are no
such things as local issues in research ethics, and suggest that those questions
currently addressed as local issues properly belong within the research governance
framework.
I
t has been widely accepted in the past
that the ethical review of research
should be carried out by a body with
some responsibility for, and knowledge
of, the local community or population
within which the research is to be
performed. In the UK the historical
development of NHS research ethics
committees (RECs) has taken place in
the context of local health service
organisational structure, with local
RECs being created and administered
as a function of the local health
authority. Traditionally this local
responsibility has been fiercely guarded,
with much being made of issues of
independence and autonomy on the
part of local committees to allow or
disallow research in their territory on
their own terms. From quite an early
stage, Department of Health1 guidelines
made provision for the delegation of
responsibility from one committee to
another:
Multicentre research: 2.18 ‘‘Each
LREC is free to arrive at its own deci-
sion when considering a proposal
which is planned to take place in more
than one area. It would, however,
obviously be sensible—in the interests
of eliminating unnecessary delay and of
ensuring that similar criteria are used to
consider a proposal—that committees
should arrive at a voluntary arrange-
ment under which one LREC is nomi-
nated to consider the issue on behalf of
them all. Health Authorities should
positively encourage networks for
neighbouring LRECs so that such co-
operation is more easily achieved’’ (DoH
1991).
However, although this was intended
to apply to studies taking place in more
than one health authority’s area, for
example in multicentre studies, in prac-
tice such cooperative arrangements
rarely occurred. Indeed, the multiple
review of multicentre studies became
so problematic that the Centre for
Philosophy and Health Care at the
University of Wales Swansea was com-
missioned to review the situation,2 and
in due course the Multi Centre Res-
earch Ethics Committee structure was
created.3
Even within the MREC-LREC system
the right of local committees to review
multicentre studies for ‘‘local issues’’
was retained and, from the perspective
of the intended cooperative working
arrangements set out in the 1991
guidance, it could be argued that ‘‘local
ethical issues’’ were invented at this
point. The recent European Clinical
Trials Directive4 seeks to streamline the
process of review and requires that
‘‘Member States shall establish a proce-
dure providing, notwithstanding the
number of Ethics Committees, for the
adoption of a single opinion for that
Member State’’. The directive also sti-
pulates that the ethics committee ‘‘shall
consider’’, among other things, ‘‘the
suitability of the investigator and sup-
porting staff’’ and ‘‘the quality of the
facilities’’ although there is no mention
in the directive of this being done at any
specifically local level, or other than as
part of the single opinion for the
Member State.
The Department of Health Governance
Arrangements for Research Ethics Com-
mittees (GAFREC)5 sets out the frame-
work for review of locality issues, which
are limited to:
N the suitability of the local researcher
N the appropriateness of the local
research environment and facilities
N specific issues relating to the local
community, including the need for
provision of information in languages
other than English.
The role of the research ethics
committee is also discussed in the
latest draft of the guidelines on good
clinical practice (GCP).6 These guide-
lines state that: ‘‘One of the res-
ponsibilities of the Ethics Committee
is to safeguard the rights, safety and
wellbeing of all trial subjects and to
provide public assurance of that
protection by, among other things,
expressing an opinion on the trial
protocol, the suitability of the inves-
tigators and the adequacy of the facil-
ities, and on the methods and
documents to be used to inform trial
subjects and obtain their informed
consent. Special attention should be
paid to trials that may include vulner-
able subjects.’’
However, there is once again no
specific reference to local review, only
the requirement that ‘‘Member States
shall establish a procedure for the
adoption of a single Ethics Committee
opinion for each Member State’’. In
providing for the possibility of the local
review of multicentre studies in the UK,
the DoH in GAFREC currently does
appear to be going beyond the require-
ments of the European directive and of
the GCP guidance.
It is, of course, entirely possible for
different individuals, acting from
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Abbreviations: EU, European Union;
GAFREC, governance arrangements for
research ethics committees; GCP, good clinical
practice; REC, research ethics committee
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sound moral principles, to come to
different conclusions about the ethical
acceptability of any given research
study. However, there is an inherent
tension in the idea that there can be
local ethical issues (as opposed, one
must presume, to ‘‘central ethical
issues’’) that render a study ethically
sound in one place and not in another.
The intention in this article is to
argue that there are no such things as
local ethical issues and that the
review of matters currently described
as ‘‘locality issues’’ should not be the
responsibility of a research ethics
committee.
ARE LOCAL ISSUES ETHICAL IN
NATURE?
The ethical review of research must
address several issues. These include,
but may not be confined to, the safety
and protection of the vulnerable human
participant, questions of equipoise and
the value of the research, the appropri-
ateness of the methods and balance of
risk and benefit, and the arrangements
for a proper, informed consent by
participants who have the capacity to
give consent. These issues are mostly
determined when a study is in the
design stage. Investigators must be able
to justify the research on the grounds
that there is a worthwhile question, to
which we do not know the answer. They
must be convinced that the question is
capable of being answered, in ways that
do not involve unacceptable danger to
participants, and must create a design
that makes appropriate use of methods
such as randomisation, blinding, pla-
cebo, takes into account availability of
other treatments for the condition in
question, is based on an adequate
sample with power to detect a signifi-
cant difference in outcome, and so on.
They then have to produce an explana-
tion of the study and all its implications
that is comprehensible to all likely
participants. In doing this they should
have in mind the probable age and
mental status of participants, and the
possible likelihood of involvement of
participants from varied ethnic or cul-
tural backgrounds. These questions will
have scientific importance, as they will
impact upon the homogeneity of the
sample and the introduction of con-
founding variables. They will also be of
ethical significance and will be the
issues that a lead or main ethics
committee will consider. The ethical
acceptability of the study design or
protocol will not, however, vary in virtue
of the locality in which the research is to
take place. We may disagree about the
use of placebo, the additional battery of
tests over and above normal treatment,
the risks that arise from the withdrawal
of standard treatment, or the accept-
ability of the use of deception, but if we
find these things acceptable or unaccep-
table we should be of the same opinion
regardless of the area in which the study
is to take place.
Local issues as implied by the
European Union (EU) directive and set
out explicitly in GAFREC, are confined
to the suitability of the local researcher,
the appropriateness of the local research
environment and facilities, and specific
issues relating to the local community,
including the need for provision of
information in languages other than
English. It would of course be unethical
to allow an incompetent investigator to
run a clinical trial at a particular centre.
It would also be unethical to present the
local ethnic community, many of whom
do not speak English, with information
and consent materials printed only in
English, or to expect an English speak-
ing child of the family to interpret these
materials for the non-English speaking
parents. But it would be equally unethi-
cal for the local NHS trust or general
practice to allow an incompetent clin-
ician to have responsibility for patient
care, or to present members of the local
ethnic community with surgical consent
forms printed only in English and to
expect the child to interpret information
about surgery or other treatment for the
parent. These are not questions of
research ethics, they are simply bad
things to do. They are of course unethi-
cal, but the ethical standard is one that
is set at the national or international
level, and not at the local.
This argument is supported by pro-
cedures that have been in place for
some time to deal with epidemiological
research and other types of study in
which there is no local researcher.
These guidelines, issued by COREC in
November 2000,7 observe that in many
types of study there is no need for there
to be a local investigator, even in some
instances in which there is patient
contact by a local clinician and the
collection of data including tissue sam-
ples. The guidelines note that ‘‘Many
LRECs themselves have questioned the
need for a local REC opinion in these
cases, as long as sufficient safeguards
are confirmed to be in place during the
ethical review of the protocol by another
REC in the NHS’’. The guidelines there-
fore establish the principle that if there
is no local investigator, there is no need
for LREC approval and thus, we must
assume, no local issues. All questions
regarding the ethical conduct of the
research are addressed by a single,
central review and any local committees
are simply notified for information.
If the key factor determining whether
or not a study needs local review is the
presence or not of a local investigator,
and it is accepted that all other ethical
questions about the conduct of the
study can be addressed centrally, this
would seem to support our argument
that all research ethics questions of
design, method, information, consent,
patient safety, and so on, can be
reviewed centrally by one committee.
None of these matters rest with the local
investigator. The only matters that could
be said to rest with the local investigator
are those things that he or she brings to
the study, which is to say his or her
expertise, conduct, and competence, and
any facilities or resources he or she may
be required to provide. The question for
local review thus is not whether the
study is ethical, but whether the local
investigator is a fit person, with ade-
quate facilities. And these questions, of
course, are not ethical but empirical. It
might be generally agreed for example
that, to be an acceptable local investi-
gator, a researcher should have an
appropriate higher degree and some
evidence of previous successful involve-
ment in research, perhaps in the form of
peer reviewed publications. The local
question of the suitability of any specific
investigator can then be answered by
reading his curriculum vitae to look for
empirical evidence of his qualifications
and publication record.
In a recent survey,8 Megone and
colleagues highlight the variation across
the EU in the local responsibilities of
RECs. Of those that are local they found
two kinds: those that oversee a local
area (as in the UK) or those that are
institutionally based (for example a
hospital committee). Apart from the
UK, only Germany, Greece, and Spain
had local RECs of the first kind and, like
the UK, consequently have a large
number of committees. A similar analy-
sis emerges from a Council of Europe
Survey,9 which says very little about the
need for local review among the 28
countries that responded. In most coun-
tries (15 of 28) RECs were hospital or
university based and in 13 they were
based on professional bodies. Most
ethical review of research within
Europe therefore takes place without
any perceived need to review ‘‘local’’
ethical factors.
WHO SHOULD BE RESPONSIBLE
FOR LOCALITY ISSUES?
The assumption that underlies the sys-
tem of local review by RECs is that,
because of their local nature, members
of an REC will have personal knowledge
of their local investigators, local health
services facilities, and the local health
economy. This may have been true
when RECs were first established 20
years ago, and may sometimes be true
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today. However, recent changes in the
NHS in England and Wales have under-
mined this position. A Health Authority
was a large entity, typically covering a
population of around 200 000 people,
and employing around 30 000 staff.
Although the proportion of staff
involved in research must be small, the
dozen or so members of the REC (a
proportion of whom would be lay) could
not have been expected to have good
personal knowledge of every local
researcher. Where members did have
personal knowledge, it was as likely to
be because of a professional or social
relationship with the individual, a situa-
tion that in today’s climate would
require at the very least a declaration
of a possible conflict of interest.
The recent changes have required a
redefinition of the research site, for the
purposes of defining a single or multi-
centre study, in England by the creation
of the Strategic Health Authority, and in
Wales by the abolition of health autho-
rities and the creation of local health
boards. It is likely that in Wales the
definition of a site will be by reference to
three regional offices for the NHS in
Wales. In both instances, the geogra-
phical area encompassed within a single
centre study will be greater than that
covered by the former health authori-
ties. Because one committee will be
required to consider a study taking place
within one of these areas, the probabil-
ity that REC members will have per-
sonal knowledge of the applicants’
competence, facilities, and resources is
accordingly diminished.
If researchers, who are likely to have
considerable personal investment in the
success of an application in financial,
academic, or professional career terms
(or all three), are to have their compe-
tence and suitability assessed by the
REC, they are surely entitled to know by
what standards and criteria, and on
what evidence this assessment is to be
made. Given the new legal status of the
RECs, a disappointed applicant, rejected
as unsuitable, would be entitled to seek
judicial review of the decision and, given
the present lack of standards or criteria,
or any systematic process of assessment,
one might suppose that the courts will
take a dim view of the REC decision
making process.
When participants are recruited to a
study through an NHS organisation, or
by virtue of their status as NHS patients,
they are entitled to expect the relevant
NHS organisation to accept responsibil-
ity for their well being in the same way
as they expect to be properly treated as
patients in receipt of care. The manage-
ment responsibility in, for example, an
NHS trust, will rest with the chief
executive and the board of directors,
but will usually be exercised through a
research and development manager, a
local research and development com-
mittee, and the research governance
framework. The governance framework
sets out the various responsibilities. For
example, the governance framework for
the NHS in Wales10 identifies the
responsibilities of the participant, the
researchers, the principle investigator,
funders, the sponsor, employing organi-
sations, care organisations, the respon-
sible care professional, and the research
ethics committee. The principle investi-
gator is responsible for ensuring that the
chief executive of the care organisation
involved in the research is informed and
that ‘‘their approval is given before the
research commences’’.
The research sponsor is ‘‘the organi-
sation taking primary responsibility for
ensuring that the design of the study
meets appropriate standards and that
arrangements are in place to ensure
appropriate conduct and reporting; the
sponsor is usually, but does not have to
be, the main funder’’. In some instances
the sponsor will be the care organisa-
tion. The sponsor is responsible, among
other things, ‘‘for ensuring the quality
of the research environment within
which the research will be undertaken
and the experience and expertise of the
principal investigator and other key
researchers involved’’. It is the respon-
sibility of the organisation providing
care to ensure that any research invol-
ving their patients, users and carers, or
staff meet the standards set out [in the
framework], in particular that it has an
identified research sponsor willing and
able to discharge its responsibilities, and
that clear and documented agreements
are in place about the allocation of
responsibilities between all parties
involved. Accountability for this lies
with the chief executive or agency
director.
Pharmaceutical industry sponsors, in
particular, have concerns about investi-
gator competence and probity, given
that they are often paying substantial
sums to local investigators. This is part
of the reason for monitors, inspections,
and so on, which have highlighted a
number of high profile cases of research
fraud.11 The local REC has rarely, if ever,
had a direct role in this and lacks the
resources and the expertise to take on
such a role. Similarly, while many
pharmaceutical sponsors offer investi-
gator training to ensure the quality of
investigator recruitment, the local REC
is not placed to make such assess-
ment and actually has never effectively
done so.
It would thus seem that, effectively,
the responsibility for ensuring the suit-
ability of the local investigator and the
research setting rests with the sponsor,
the principle investigator, and the care
organisation. This has clear advantages.
All of these bodies or individuals will
have personal knowledge of the
researcher, and the opportunity and
means to assess his or her competence
and suitability. They will also have clear
organisational responsibility, account-
ability, and liability for both the conduct
of the researchers and the research in
ways that the REC cannot possibly have.
The present guidelines, however, would
result in duplication of effort. While the
Research Governance Framework places
the responsibility with the sponsor, the
principle investigator and the care orga-
nisation, the European directive and
GAFREC both charge the ethics com-
mittee with responsibility for the suit-
ability of the researcher and the local
facilities.
REASSURING THE PUBLIC
One further role of the local REC may be
suggested: that it provides reassurance
to the local community of the validity of
ethical review. Indeed this is explicitly
stated in the ICH GCP guidelines, which
state that ‘‘one of the responsibilities of
the Ethics Committee is…to provide
public assurance of that protection’’.
Similarly, in the UK, the Guidelines on
the Practice of Ethics Committees in
Medical Research from the Royal
College of Physicians state: ‘‘The objec-
tives [of ethics committees] are…to
provide reassurance to the public that
this [protection of subjects] is being
done’’.12
From this perspective lay members of
RECs particularly might be thought to
be there to make the committee more
democratically representative, more
representative of the community as a
whole, or more accountable to the
community as a whole. Local review
may not alter the ethics of a study, but it
could be seen to be a useful check, a
reassurance that justice is seen to be
done. However, even if we believe this
function to be necessary, we might
nevertheless question whether the local
REC can perform it.
To suggest the need for RECs to be
responsible for such a check is to
suggest that the REC is the only body
concerned with the ethics of a study.
This is not the case: research sponsors,
NHS bodies hosting research, and the
investigators themselves all share this
responsibility. RECs may have a key role
in ethical opinion making but no one
suggests that their role is an exclusive
one, or that research sponsors and
investigators are not responsible for
proposing ethical research. The role of
the local REC in providing a further
check may therefore be no more than
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another obstruction. Not all obstruc-
tions are necessarily a bad thing, but
given an effective system of main ethical
review, a proper governance structure,
and the lack of training of many local
REC members, it is an obstruction that
probably serves no useful purpose and
should be avoided.
It is doubtful in any case that REC
members are, in any meaningful sense,
locally representative. In big cities espe-
cially, they often reside outside the
catchment areas of the institutions in
which the research is to take place. They
are not elected and, in the past, have
often achieved their place on the REC by
invitation. Some—perhaps clergy are a
good example—may have excellent
community credentials, but others, such
as non-executive directors of trusts,
have none and represent another voice
from the articulate middle classes, who
are already well represented by the
professional members. If those objec-
tions were not sufficient, the restructur-
ing of the NHS, with strategic health
authorities in England and the abolition
of health authorities in Wales, means
that the claim that the LREC can
represent a community becomes even
more difficult to sustain. It is therefore
hard to see how a local REC could give
adequate reassurance to the local com-
munity beyond that already offered by
the central committee. Local REC
annual reports are currently the only
vehicle of accountability and the profile
of the REC is close to invisible in most
communities. It is doubtful if most
annual reports achieve even a sentence
or two in the local newspaper.
It might be argued that a research
project could be unethical if it offends in
some way against cultural or social
norms, which might be locally deter-
mined. The debate about cultural rela-
tivity in ethics is rather beyond the
scope of this paper, but it is generally
the case that we respect cultural prac-
tices relating to such things as diet,
worship, or dress, while not accepting
practices such as female circumcision,
forced marriage, or the immolation of
widows. However these conventions are
established at a national level and
would be the responsibility of central
ethical review, the local investigator,
and local governance arrangements.
There are also more localised concerns,
which may relate to a particular sensi-
tivity in a particular community. A
project on some aspects of community
paediatrics and child protection, for
example, might be thought inappropri-
ate in a small town like Soham where a
particularly high profile case of child
murder took place in 2002. If this is an
ethical objection, it is at a level at least
one step removed from research ethics,
being more about a general feeling that
one should not do something that might
cause offence or distress. This would
elevate ‘‘appropriateness’’ into an ethi-
cal principle to be balanced alongside
others, although it is interesting to note
that, as far as we are aware, there is no
objection to research into the manage-
ment of trauma in Northern Ireland,
or into the after effects of exposure
to radiation either from the bombs
dropped on Nagasaki and Hiroshima or
the nuclear accident at Chernobyl.
A local REC might be thought to be
best placed to judge such matters of
local acceptability, if it were a truly local
and representative body. On the other
hand, this sort of reservation could
equally apply to an epidemiological
study, where there is no local researcher
and thus no requirement for local
ethical review and so this may be
another example where responsibility
is best devolved to the research and
development structure of a trust or
primary care body. The question is not
about the ethics of the study protocol
itself but about its acceptability at a
particular time and place. Such cases are
likely to be very rare and hardly justify
an elaborate system of review by com-
mittee. It should be sufficient simply to
build into the review of all protocols a
requirement for local investigators to go
through local research and development
bodies, who should ensure that an
awareness of local sensitivities forms
part of their decision making. There is
no reason to believe that the local REC
would be any more knowledgeable of
local recent history or other sensitivities,
given its unrepresentative nature and
the extent of the geographical area it
must oversee, so even if such pragmatic
issues were to be viewed as ‘‘ethical’’,
one can still doubt whether the REC is
the most competent body to deal with
them.
A WAY FORWARD
The recruitment of sites is the responsi-
bility of the principal investigator, who
is also (with others) responsible for
ensuring the suitability of the local
researcher and the local facilities. He or
she must also ensure that the chief
executive of the care organisation
responsible for the care of the partici-
pants gives his or her approval. The chief
executive shares responsibility for
ensuring that the local investigator is
acceptable and that the resources and
facilities are in place, and he or she is
liable for any harm that may befall
patients in his or her care.
When the principal investigator seeks
ethical approval, he or she will include
details of the sites and local researchers
recruited so far with the application. If
the principal investigator is required to
submit that information together with a
signed statement from the respective
chief executives to the effect that the
research has been approved within the
research governance framework for
the care organisations, the REC review-
ing the proposal will know that a
properly responsible and accountable
body has accepted responsibility and
liability for the local researcher and
research facilities in each site. Thus the
study would need no further review
beyond the main ethical review by the
REC. Sites and local investigators
recruited after ethical approval had been
received would be notified to the REC,
with the letter of governance approval
from the chief executive. As an aside, we
note that because RECs are advisory
bodies only (and with respect to ethics,
not monopoly ones), it is possible in
principle that the research and develop-
ment committee or even the chief
executive could prevent the study locally
on ethical grounds, as well as on
grounds of research governance.
For research in NHS hospital trusts
this arrangement would be relatively
straightforward. In primary care, where
general practitioners (GPs) conduct
research either as principal or local
investigators, it may not be quite so
clear. The requirements of the govern-
ance framework are clear enough, but it
is not immediately obvious as to who
should function in the various roles, as
the GP researcher may also be the chief
executive of the care organisation and in
some instances might also be the
sponsor. However, the GP’s patients
are under his or her care by virtue of
the contract to provide general medical
services, and thus it would seem reason-
able for the body that controls and
monitors this contract to accept respon-
sibility for the research activities of GPs
and monitor their performance; in
Wales for example this would be the
local health board. In both the hospital
and the primary care settings there is
also the possibility of conflicts of inter-
est. Research, particularly when funded
by the pharmaceutical industry, may
generate considerable income for the
local investigator, and a successful
research career may also bring consider-
able prestige and professional advance-
ment for the researcher. Hospital trusts
may rely on research income to sub-
sidise clinical services, members of staff
may depend on it for their continued
employment, and GP practices may
depend on it to fund posts or other
activities. However the governance
structure, while not guaranteeing that
there will be no abuses of the system,
does at least provide a system of
regulation and accountability through
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which action can be taken should
malpractice be identified.
SUMMARY AND CONCLUSIONS
We have argued in this paper that the
only questions of research ethics relat-
ing to studies reviewed by RECs are
central issues: the REC reviews the
ethics of the study. It would be unethi-
cal to allow incompetent researchers to
conduct research in inadequate facil-
ities, but this is not a question of the
ethics of research. The competence of
the investigator and the suitability of
the facilities are empirical questions that
the REC is not competent to address and
these are issues that should be outside
the responsibility of the REC. The
responsibility for the management and
conduct of research rests with the
sponsor, the principal investigator, and
the care organisation and this is well
described in the Framework for
Research Governance.
The locality issues set out in GAFREC,
of the competence of investigators and
suitability of facilities, should thus be
addressed through the governance
framework and not through the REC
system. Applicants for ethical review
should present their protocols with
details of sites and local researchers
already approved by the relevant
authority through governance proce-
dures, and the convention of local
review by the REC should be aban-
doned. Research ethics committees
should, however, be notified of research
to be conducted in their area, as they are
with current studies where there is no
local researcher. As part of the main
ethical review, RECs should satisfy
themselves that there has been proper
scrutiny of the project through the local
research governance framework in each
of the proposed sites and that the
appropriate local manager has accepted
responsibility for the conduct of the
research. The requirement set out in the
European directive for RECs to ‘‘con-
sider’’ such issues as the suitability of
the local investigator and quality of
facilities can thus be fulfilled by scrutiny
of the local governance agreement. This
also fulfils the requirements of the
Directive that protocols undergo ethical
review by a single body.
There may be some concern that
governance arrangements are in their
infancy and not yet sufficiently robust
to provide sufficient reassurance of the
protection of the research participant. If
this is the case, the problems should be
addressed by strengthening the govern-
ance system. After all, it is the sponsor,
principal investigator, and care organi-
sation who are responsible for the
conduct of the research and the safety
of all involved and who will be held
accountable and liable in the event of
any damage to research participants.
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